Get Started with NeoGenomics
IHC & ISH
NeoTYPE® Cancer Profiles
NeoLAB EGFR T790M – Liquid Biopsy testing is now being offered at NeoGenomics Laboratories to detect the T790M acquired resistance mutation with very high sensitivity (0.1%) using cell-free circulating tumor DNA. This new assay provides a powerful alternative for situations involving limited access to tissue samples.
For NSCLC patients that have developed an acquired resistance to prior TKI treatment and are suspected to have an EGFR T790M acquired resistance mutation. Helpful in situations where limited or no tissue is available for testing and for identifying patients that may respond to third generation EGFR TKIs.